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Purpose: Ethacrynic acid (ECA) is a potential trabecular meshwork (TM) drug that has shown promising results in
preclinical studies for treatment of primary open-angle glaucoma. However, topical application of ECA is currently limited
by adverse effects in corneal tissues. To this end, we developed a new theoretical model to evaluate time-dependent toxicity
induced by ECA in corneal epithelial cells.
Methods: The model consisted of a cellular pharmacokinetic (PK) module to determine intracellular concentration of
ECA, and a pharmacodynamic (PD) module to determine the cytotoxicity of ECA. It was assumed that ECA-induced
cytotoxicity depended on drug exposure time and peak concentration of bound ECA in cells. In addition to the model
development, we experimentally determined the intracellular concentration of ECA as a function of drug dose and
treatment time.
Results: The intracellular concentration increased linearly (i.e., no saturation) with increasing the dose of ECA. It also
increased initially with time and then reached a steady-state at ~40 min. The percent of cells survived after treatment
decreased with increasing the dose of drug or the time of treatment. The experimental data were fit by the new PK and
PD models to obtain values of model constants. One of the unique applications of these models was to predict cell survival
relative to control when extracellular concentration of ECA varied with time. The prediction showed that the toxicity of
ECA might be significantly overestimated by using the traditional LC50 determined in vitro.
Conclusions: The new PK and PD models developed in this study were capable to fit experimental data and predict time-
dependent toxicity of ECA in corneal epithelial cells. The models may be useful for optimizing the dose and schedule in
topical application of ECA for glaucoma treatment.
Ethacrynic acid (ECA), a potential trabecular meshwork
(TM) drug, has shown promising results in pre-clinical studies
to treat primary open-angle glaucoma [1-6]. The efficacy of
treatment depends on how much ECA can be delivered to TM
tissues. Although different approaches to drug delivery to the
anterior chamber have been developed [7-10], the preferred
choice  is  still  the  topical  application  because  of  its  non-
invasiveness and convenience in the clinic. The efficiency of
topical application is currently limited by adverse effects of
drugs in corneal tissues observed at the dose required for
achieving a therapeutic concentration in the TM [6,11]. To
overcome the toxicity problem, it is important to understand
mechanisms of toxicity in corneal epithelial cells and develop
novel techniques to accurately evaluate the toxicity. A widely
used parameter for toxicity evaluation in vitro is the lethal
concentration at which 50% of cells are killed (LC50) when the
cells are continuously exposed to the drug for a certain period.
If extracellular concentration of a drug varies significantly
with time, which often happens in vivo, the LC50 becomes
meaningless.  In  this  case,  other  quantities  need  to  be
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considered for the evaluation of drug toxicity. For example,
one can quantify the toxicity by using the area-under-the-
curve  (AUC)  at  which  50%  of  the  cells  are  killed  after
treatment (AUC50). Experimentally, it is feasible to determine
LC50 or AUC50 by treating the cells of interest with specific
drugs for a short period (e.g., a few hours), but it is difficult
to perform long-term (e.g., a few weeks) experiments. This is
because primary cells have only limited life span in culture
and immortalization of these cells may cause changes in their
characteristics. One alternative approach to addressing the
long-term  toxicity  issue  is  to  develop  cellular
pharmacokinetic (PK) and pharmacodynamic (PD) models
and used them to simulate dose response curves in terms of
cell survival under different experimental conditions.
The development of PK models can be straightforward
since drug transport and reactions are governed by general
principles.  On  the  other  hand,  PD  models  depend  on
mechanisms of drug actions in cells and molecular properties
of drugs, which may be unknown in many cases. Despite of
this challenge, various PD models have been developed to
predict how cell survival relative to the control, S, depends on
drug concentration and treatment period. Quantitatively, S is
defined as the number of cells survived after drug treatment
divided by the number of live cells in untreated control. The
drug concentration in a PD model may refer to intracellular
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2507concentration, extracellular concentration, or the combination
of the two. When the concentration is time-dependent, it may
refer  to  peak  concentration.  Furthermore,  S  is  an  explicit
function of drug concentration and exposure time in some
models  but  an  implicit  function  in  other  models  where
concentration and time are included through AUC or other
quantities (see the Methods section) [12-15]. In many studies,
S  is  assumed  to  be  a  sigmoidal  function  that  can  be
approximated by a Hill-type Equation [13,14].
The goal of this study was to develop a new theoretical
framework consisting of cellular PK and PD modules. The
new model can be used to investigate ECA induced toxicity
in  corneal  tissues,  and  to  facilitate  development  of  novel
strategies for improving topical drug delivery by combining
it with mathematical models of ECA transport in the eye
[16].
METHODS
Cell culture: Corneal epithelium was removed carefully from
corneal  grafts  in  fresh  enucleated  porcine  eyes,  using  a
surgical scalpel, and placed into a 50 ml beaker with Hank’s
balanced salt solution (HBSS; Gibco, Grand Island, NY) and
2% penicillin/streptomycin at room temperature. After 5 min,
the corneal epithelium was digested using protease (Sigma,
St. Louis, MO) for 60 min, and the solution was centrifuged
at 704× g for 5 min to remove the enzyme. The corneal
epithelium was further digested using collagenase (Type IA;
Sigma) for 90 min. After digestion, the solution was filtered
through a sterile cell strainer (40 μm Nylon; BD Biosciences,
Franklin Lakes, NJ) and centrifuged at 704× g for 5 min. The
primary porcine corneal epithelial cells (PCEC) harvested
were  then  re-suspended  in  culture  medium  containing
DMEM-F12 (BioWhittaker, Walkersville, MD), 10% fetal
bovine  serum  (FBS),  0.02  mg/ml  gentamicin,  2  mM  L-
glutamine,  0.5%  dimethyl  sulfoxide  (DMSO),  5  μg/ml
insulin,  1%  penicillin  and  streptomycin,  and  10  ng/ml
recombinant  human  epidermal  growth  factor  (EGF),  and
cultured at 37 °C with 5% CO2 and 95% humidified air. After
reaching confluence in the flask, the cells were transferred
onto 24-well plates at a density of 105 cells per well, and
cultured for three to five days until confluent monolayers were
formed. At this stage, the cell density was approximately
4×105 cells per well. These cells at the first passage still
retained the epithelial phenotype. Thus they were used in all
experiments described below.
Uptake of ECA by primary corneal epithelial cells: Confluent
primary  PCECs  were  cultured  in  24-well  plates.  Before
adding ECA solutions, the culture medium was removed, and
the cells were washed three times with HBSS to remove the
remaining culture medium. The cells were then exposed to
1 ml HBSS containing different concentrations of ECA (50,
100, 200, 300, and 600 μM) for varying periods (0.5, 2, 8, 15,
and 45 min). After ECA treatment, the drug solution in each
24-well plate was collected for offline analysis. The cells were
washed twice with fresh HBSS; and the resulting solutions
were also collected for offline analysis. All experiments were
performed in triplicate.
The three solution samples collected in the experiment
described above were analyzed by high-performance liquid
chromatography (HPLC). The data showed that the amount
of ECA in the third sample was negligible, and that there was
a significant ECA loss in the second sample,  compared  with
ECA concentration in the first one. The question was, how
much of the ECA loss was due to ECA internalization by
cells? In a previous study, Tirona et al. [17] observed that
when hepatocytes were treated with ECA in vitro, the loss of
extracellular 14C-ECA was completely accounted for by the
formation of ECA-glutathione (GSH) conjugate within cells,
and that the total mass of ECA was conserved throughout the
entire  treatment  period.  Therefore,  we  assumed  that  the
amount of cellular uptake of ECA was equal to the amount of
loss  of  extracellular  ECA.  Based  on  this  assumption,  the
reported intracellular concentration was calculated as the total
amount of extracellular ECA loss divided by the total volume
of cells in the monolayer.
Determination of ECA concentration by HPLC: The HPLC
measurement was performed using an Inertsil ODS-3 5U,
4.6 mm i.d.×250 mm (Varian Inc., Palo Alto, CA) with a
mobile  phase,  H2O:  acetonitrile:  acetic  acid  (49:49:2  by
volume), at flow rate of 1.0 ml/min. The detector for UV
absorbance  was  set  at  270  nm  instead  of  230  nm  due  to
possible interference of ECA spectrum with that of GSH at
230 nm (see Figure 1). All sample solutions were filtered
through a 0.2 μm AcroPrepTM 96 filter plate (Pall Corporation,
Ann Arbor, MI) before being transferred into a 384-well plate
for HPLC analysis. The volume of each injection was 50 μl,
and the running time was 30 min. System calibration was
performed for each individual HPLC analysis by comparing
the peaks of absorbance to the known concentrations of ECA.
All measurements were performed within the linear ranges of
the calibration curves. The concentration in each sample was
first determined in μM and then converted to nmol/(105 cells)
in 24-well plates, based on sample volume and cell density in
each well.
Determine cytotoxicity of ECA in porcine corneal epithelial
cells in vitro: Primary PCECs at the first passage were placed
in 96-well plates at a density of 1×104 cells/well. After 24 h,
the culture medium was replaced with 100 μl of fresh medium
containing ECA at different concentrations: 0, 10, 30, 50, 75,
100, 200, 300, or 600 μM. The cells were treated for 2, 6, 24,
or  72  h.  After  treatment,  cell  viability  in  all  groups  was
measured by using CytoTox 96 kit (Promega, Madison, WI).
The ratio of the numbers of viable cells between treated and
untreated  (i.e.,  at  zero  concentration  of  ECA)  groups  is
reported as the survival relative to control (S). All assays were
performed in quadruplicates and the mean value is reported in
this paper.
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determine the intracellular and extracellular concentrations of
ECA under different conditions. The schematic representation
of the model is shown in Figure 2. The model development
was based on the following considerations. First, ECA can be
metabolized  in  cells  [18,19].  Yamamoto  et  al.  [19]  have
measured concentrations of ECA metabolites in isolated rat
hepatocytes. The data demonstrate that they are significantly
lower than ECA concentration after cells are treated with the
drug for 30 min, and the metabolic rate can be reduced by an
inhibitor of cytochrome P450. In this study, we used corneal
epithelial cells, which were expected to metabolize ECA at a
lower rate, compared to hepatocytes. Thus, ECA metabolism
was neglected in our PK model. Second, ECA in solutions can
be degraded as well. However, data in the literature showed
that ECA at 0.1 mg/ml was stable in 100 mM potassium
phosphate buffer at pH 7.4 for at least 6 h [20]. In another
study, only 17% of ECA at 0.05 mg/ml was degraded after the
solution  was  stored  for  480  h  at  60  °C  and  pH  8  [21].
Significant degradation of ECA occurred only at pH 10 and
pH 12. In our experiments, we only used fresh ECA solutions
prepared on the same day, and all samples were analyzed by
HPLC immediately after cell incubation. Thus, extracellular
degradation  of  ECA  was  negligible.  Third,  different
mechanisms  can  be  involved  for  cellular  uptake  of  ECA.
Active  transport  may  exist  in  liver  cells  [22],  but  is
insignificant  in  confluent  rat  renal  proximal  tubular  cells
[23], and cells in rabbit kidney cortex [24]. Active transport
can  be  modeled  in  pharmacokinetic  analysis  by  adding  a
saturable component in the equation for rate of cellular uptake
Figure  1.  UV  absorbance  spectrums  of  ECA  and  GSH.  The
concentrations  of  ECA  and  GSH  were  50  μM  and  600  μM,
respectively. The spectrum curves suggested that ECA concentration
should be measured at 270 nm to minimize possible interference with
signals from GSH.
[17]. However, this addition would be inconsistent with our
experimental data obtained in corneal epithelial cells (see the
Results  section),  which  showed  that  the  uptake  rate  was
approximately a linear function of extracellular concentration
of  ECA.  Therefore,  the  saturable  component  or  active
transport was neglected in our PK model. Fourth, efflux of
ECA-glutathione  conjugate  has  been  considered  in  PK
analysis of ECA using rat hepatocytes [17]. It was an order of
magnitude slower than the passive diffusion of ECA. Thus,
efflux of ECA conjugated with endogenous molecules (e.g.,
GSH) was neglected in our PK model as well. Taken together,
we assumed that ECA entered into and moved out of cells
through passive diffusion. As a result, the mass balance for
ECA in cells is governed by Equation 1;
dCit
dt
= Pm(Ce − Cif ) (1)
where Cit is the total intracellular concentration of ECA; Ce is
the extracellular ECA concentration; Cif is the intracellular
concentration  of  free  (unbound)  ECA;  and  Pm  is  the
permeability coefficient of cell membrane. Within the cell,
ECA could bind to various intracellular targets (e.g., GSH),
which were lumped together and represented by G in the PK
model  (see  Figure  2).  Previous  studies  have  shown  that
binding  of  ECA  to  GSH  is  significantly  faster  than  its
diffusion into cells [17,20]. Therefore, binding was assumed
to  be  at  a  quasi-equilibrium  state,  and  the  equilibrium






Figure 2. Schematic representation of the proposed pharmacokinetic
model. The definition of each term is as follows: Ce: extracellular
ECA concentration; Cif: intracellular concentration of free (unbound)
ECA; G: intracellular binding site available to ECA; G-ECA: bound
ECA;  Cib:  intracellular  concentration  of  bound  ECA;  and  Pm:
permeability coefficient of cell membrane.
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2509where  Bmax  is  the  maximum  concentration  of  intracellular
binding sites for ECA and KD is the equilibrium dissociation
constant. The total intracellular ECA concentration was the
sum of Cif and Cib;
Cit = Cif + Cib (3)




(KD + Cif )2
(KD + Cif )2 + KDBmax
(Ce − Cif ) (4)
For  a  given  dose  or  initial  concentration  of  ECA  in  the
extracellular medium (Ce0), Ce was determined by using the
mass balance equation;
CeVo + (Cif + Cib)Vi = CeoVo (5)
where Vo is the volume of extracellular ECA solution, Vi is the
total  volume  of  intracellular  space,  which  was  calculated
based on the number of cells per well, assuming that the cell
was spherical and had a diameter of 21 μm [25]. Substituting






(KD + Cif )2
(KD + Cif )2 + KDBmax
CeoVo − (Cif +
Bmax Cif
KD + Cif )Vi − Cif Vo
(6)
Equation 6 was solved numerically to obtain Cif, which was
then substituted into Equations 2 and 3 to obtain Cit. The
values of Pm, KD, and Bmax were determined by fitting the
experimental data with the predicted values of Cit using a
nonlinear  least  square  method  (MATLAB  software;  The
Mathworks Inc., Natick, MA).
Cellular PD model: To evaluate survival of primary PCECs
treated with ECA under different conditions, a cellular PD
model was developed based on the Hill-type equation;
S =
1
1 + Ax m (7)
where A and m are constants. The quantity x is a function of
drug concentration and exposure time, which was determined
based on the following considerations. It has been proposed
that  ECA-induced  cytotoxicity  is  mediated  partly  through
depletion of GSH in both cytosol and mitochondria, which has
been  observed  experimentally  in  hepatocytes  [19,26],
cerebellar astrocytes [27], and motor neurons [28,29]. When
the GSH level is reduced to 20%–30% of its normal level, a
large amount of reactive oxygen species are produced in cells,
which may cause cell death [29]. It has been hypothesized that
ECA  can  deplete  intracellular  GSH  through  three
mechanisms: (1) direct (non-enzymatic) interaction with GSH
to form thiol adducts through a Michael-type reaction; (2)
conjugation with GSH catalyzed by glutathione S-transferases
(GSTs) [19,27,30]; and (3) inhibition of GSH biosynthesis
through irreversible conjugation with glutathione reductase,
which is an enzyme that catalyzes the reduction reaction to
convert  glutathione  disulfide  (GSSG)  to  GSH  [19,30-32].
Experimental data in the literature have also suggested that
other intracellular protein sulfhydryls may contribute to the
ECA-induced cytotoxicity. For instance, microtubule and F-
actin assembly in cells can be affected by ECA [33-38]. Motor
neurons  exhibit  chromatin  condensation  and  nuclear
fragmentation at 3 h post ECA treatment at 100 µM [28],
indicating that DNA is also an intracellular alkylating targets
of ECA.
Based  on  the  discussion  above,  x  in  Equation  7  was
assumed to be a function of the peak concentration of bound
ECA in cells, (Cib)p, and the time, tp, at which Cib reached its
peak level, i.e., x=f[tp, (Cib)p]. If Cib was increased gradually
and reach a plateau, there would be no peak concentration. In
this case, (Cib)p would refer to the maximum value of Cib, and
tp would be the total treatment period. Various forms of f have
been proposed in previous studies for fitting experimental data
[13]. The form choice is not necessarily to be unique for a
given set of data. In this study, we assumed that f was a power






where n is a constant and the power raised for (Cib)p can be
absorbed into m in Equation 7. Thus, it is not explicitly shown
in Equation 8. Substituting Equation 8 into Equation 7 yielded
a  new  equation  that  was  used  to  fit  the  cytotoxicity  data
obtained  in  this  study  to  determine  the  values  of  three
constants, A, n, and m, using the nonlinear least square method
in MATLAB software (The Mathworks Inc.). Similar to most
PD models in the literature, our model assumed implicitly that
the values of Pm, KD, and Bmax determined in a relatively short-
term  PK  experiment  were  still  valid  in  the  cytotoxicity
analysis.
Simulation of drug toxicity due to transient exposure to ECA:
The PK and PD models would be applied to predicting ECA
toxicity in corneal tissues in the following two scenarios of
drug delivery: (i) topical application of ECA as eye drops and
(ii) sustained release of ECA in the pre-corneal region from a
copolymer film containing 21% Pluronic® F127 and 10%
Pluronic® F68 [39]. In each scenario, drug clearance in the
pre-corneal  region  was  approximated  by  the  first-order
kinetics. The estimated half-lives for these scenarios were 3.0
min and 30.3 min, respectively [39,40]. The concentrations of
ECA in the pre-corneal region in the first and second scenarios
were given by;
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−0.231t for t>0 (9)
Ce2 = Ce0e
−0.0229t for t>0 (10)
respectively, where Ce0 is the initial ECA concentration and
t is the exposure time.
RESULTS
Figure 3 shows the intracellular concentration of ECA (in
nmol/105 cells; Cit) after PCECs were treated with ECA for
different time periods. It is plotted as a function of the initial
concentration of ECA in extracellular medium (Ce0). The data
demonstrated  that  Cit  was  considerably  higher  than  the
corresponding value of Ce0, which in turn was higher than the
extracellular concentration of ECA at the end of treatment,
suggesting that the majority of ECA molecules in cells were
bound to intracellular substrates. The data also showed that
the intracellular concentration was linearly dependent on Ce0
(i.e.,  no  saturation)  if  the  drug  exposure  time  was  fixed,
suggesting a very high concentration of binding sites available
to ECA in cells.
The data shown in Figure 3 were re-plotted to show time-
dependent changes in intracellular concentration of ECA (see
in Figure 4). The data were fit by the PK model described in
the Methods section; and the best-fit values of the model
constants are reported in Table 1. The concentration profiles
indicated that the rate of cellular uptake of ECA, i.e., the
slopes  of  the  curves,  decreased  with  increasing  the  drug
exposure time, which was expected since the diffusion of ECA
into cells would reduce concentration difference across the
cell membrane. The concentrations reached steady-states at
~40 min.
The number of PCECs survived after ECA treatment was
quantified and normalized by the number of viable cells in the
untreated group. It was a function of the initial concentration
of ECA in the extracellular medium and the drug exposure
time. Data shown in Figure 4 indicated that Cif and Ce could
be assumed to be equal to each other for time longer than 2 h.
By  using  this  information  and  simultaneously  solving
Equations 2, 5, and 7 described in the Methods section, S could
be expressed as a function of Ce0 and tp. This expression was
then used to fit the experimental data obtained in this study,
which  yielded  the  values  of  constants  in  the  PD  model:
A=1.53×1013, n=0.3, and m=7.48 if the unit of time was hour.
The results of curve-fitting are plotted in Figure 5. The PD
model predicted that the LC50 of ECA, in terms of Ce0, were
227, 163, 107, and 77 µM for the PCECs treated continuously
with ECA for 2, 6, 24, and 72 h, respectively.
To simulate ECA toxicity in corneal epithelial cells when
the drug was administered topically on the corneal surface for
glaucoma  treatment,  Equations  9  and  10  were  used  to
determine Ce, the concentration of ECA in the pre-corneal
region.  Two  scenarios  of  topical  drug  delivery  were
considered here: traditional eye drop and sustained release of
ECA from Pluronic® copolymer film. The time dependent
profiles of Cif in epithelial cells on the cornea surface were
determined by solving Equation 4, where Ce was a given
function of time. Substituting Cif into Equation 2, the peak
level of Cib and the corresponding tp were determined, which
were both functions of Ce0. These values were then substituted
into Equation 7 to determine the survival relative to control,
S.  The  simulation  results  are  shown  in  Figure  6.  To
Figure 3. Intracellular concentration of ECA. It was a function of the
initial  extracellular  concentration  of  ECA  and  the  period  of
treatment.
TABLE 1. VALUES OF FITTED PK AND PD MODEL CONSTANTS.
Constant Description Value
Pm Permeability coefficient of membrane 0.003213 ml/(min 105 cells)
KD Equilibrium constant for GSH conjugation 13,800 μM
Bmax Maximum substrate concentration 541 nmol/105 cells
A Constant in the PD model 1.53×1013
n Constant in the PD model 0.3a
m Constant in the PD model 7.48a
               aThe values of m and n depended on the choice of time unit. It was required to be “hour” for the values listed here.
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constant and transient exposures of cells to ECA, S was also
simulated when the concentration of ECA in the pre-corneal
region was fixed at a constant level over a long period (e.g.,
1,000 h). It was observed that the survival profile shifted to
the left when the exposure time was increased; and the amount
of shift diminished if the time was longer than 1,000 h (data
not shown). Therefore, we only plotted the survival curve after
cells  were  continuously  treated  with  ECA  at  a  fixed
extracellular concentration for 1,000 h. The values of LC50 in
terms of Ce0 were calculated; they were 2330 μM, 540 μM,
and 35 μM, respectively, for the three different scenarios of
drug delivery. When comparing the curves shown in Figure 6
with those in Figure 5, it could be observed that for the same
Ce0, LC50 in a transient exposure scenario was several folds
higher  than  the  value  in  the  constant  exposure  scenario,
indicating that transient exposure could significantly reduce
drug toxicity.
DISCUSSION
New  cellular  PK  and  PD  models  were  developed  for
investigation of drug toxicity in cells. They could predict the
survival  relative  to  control  when  cells  were  exposed
transiently to the drug. Results from this study suggested that
the  toxicity  of  ECA  in  corneal  tissues  was  significantly
overestimated by using the traditional LC50 since the clearance
of  ECA  in  the  pre-corneal  region  was  not  considered  in
previous toxicity studies.
To validate the PK and PD models, we compared results
in this study with those in the literature. First, we did the
comparison for ECA uptake by different types of cells. Tirona
et al. [20] observed that the initial rate of ECA uptake by
Figure 4. Time dependent changes in intracellular concentration of
ECA. The symbols indicate experimental data and the curves were
resulted from fitting the PK model to the data. The best-fit values of
the model constants are reported in Table 1.
cultured hepatocytes was 0.62 nmol/(min•105 cells) when the
initial  concentration  of  ECA  was  given  at  200  μM  in
extracellular  medium.  This  data  was  close  to  0.60  nmol/
(min•105 cells) observed in this experiment. Haenen et al.
[23] investigated ECA uptake by cells after adding 1 ml of
14C-labeled ECA solution (14 μM) on top of a monolayer with
2×105 rat renal proximal tubular (RPT) cells. After 30 min,
90% of the radioactivity was recovered from the medium,
suggesting that 10% of ECA in the medium was internalized
by RPT cells. We did not perform the uptake experiment under
the  same  experimental  conditions,  but  the  data  could  be
compared with the PK model prediction. Assuming the initial
concentration of ECA, the exposure time, and the cell density
to  be  14  μM,  30  min,  and  2×105  cells  per  monolayer,
respectively, the model predicted that 93% of ECA in the
medium above a PCEC monolayer could be recovered, which
was close to the data reported in the previous study [23].
Intracellular  concentration  of  unbound  ECA  was  not
quantified  in  this  study  since  it  was  found  that  the
concentration was below the limit of detection in our system.
On the other hand, our PK model predicted that the majority
of intracellular ECA molecules were in the form of bound
species. The prediction was consistent with those observed in
a previous study [17], where the authors demonstrated that the
intracellular concentration of unbound ECA was minimal,
compared to that of ECA-GSH conjugate.
The data of cellular uptake could further be compared
qualitatively to those related to GSH depletion since the latter
was caused by the former (see the Methods section). Figure 3
Figure 5. Experimental data of cell survival relative to control (S). It
was a function of the initial extracellular concentration of ECA and
the period of treatment. The symbols indicate experimental data and
the curves were resulted from fitting the PD model to the data. ●: 2
h of constant ECA exposure; ▲: 6 h of constant ECA exposure; ♦:
24 h of constant ECA exposure; ◊: 72 h of ECA exposure. The best-
fit values of the model constants are reported in Table 1.
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approximately linearly with increasing the initial extracellular
concentration  of  ECA  for  all  exposure  times,  which  was
consistent with the observation that the loss of GST activity
was  linearly  dependent  on  the  initial  extracellular
concentration up to 2 mM when cells were treated with ECA
for 30 min [41]. Figure 4 shows that the intracellular ECA
concentration profiles increased with time initially and then
reached a steady-state at ~40 min. If these curves were flipped
vertically,  they  were  comparable  to  the  time-dependent
profiles  of  the  intracellular  GSH  concentration  in  rat
hepatocytes  treated  with  ECA  [19].  In  a  similar  study,
Rizzardini et al. [28] showed that when motor neuron cells
were treated continuously with ECA solution at 100 μM, the
intracellular GSH level dropped to 25% of its initial level at
1  h  and  became  undetectable  within  4  h.  Furthermore,
Yamamoto et al. [19] demonstrated that intracellular protein
sulfhydryls in isolated rat hepatocytes were 30% and 25% of
the initial concentration at 1 h and 3 h, respectively, when cells
were treated continuously with ECA solution at 1 mM. These
data suggested that the rate of GSH depletion was on the same
order of magnitude as that of cellular uptake of ECA.
The toxicity data obtained in this study were compared
quantitatively with those in the literature. It has been shown
that ECA solution at 66 μM had no apparent cytotoxicity for
human fibroblasts in vitro when the cells were treated for 2 h.
However, the ECA solution became toxic when the treatment
was increased to 6 days [42]. To compare with these data, we
Figure 6. Cell survival relative to control simulated by using the
cellular PK and PD models. S was plotted as a function of the initial
concentration of ECA in the extracellular medium for three different
scenarios of topical drug delivery in the eye. (i) ECA was applied via
traditional eye drops (LC50=2330 μM); (ii) ECA was released from
a  Pluronic®  copolymer  film  (LC50=540  μM);  and  (iii)  ECA
concentration at corneal surface was maintained at constant levels
for 1,000 h (LC50=35 μM).
calculated the LC50 values using the PK and PD models. They
were 227 μM and 54 μM for PCECs treated with ECA for 2
h and 6 days, respectively, suggesting that the ECA solution
at 66 μM was non-toxic to PCECs if the drug exposure time
was 2 h but would be severely toxic if the period of treatment
was  increased  to  6  days.  In  another  study,  the  LC50  was
determined to be 158 μM when primary bovine TM cells were
treated with ECA for 3 h [5]. Using the PK and PD models
developed in this study, it was predicted to be 174 μM, which
was on the same order of magnitude as that for the TM cells.
The cellular PK and PD models developed in this study
can be used to predict ECA toxicity in epithelial cells on the
surface of cornea when the drug is applied topically. It has
been shown that the ECA concentration in the pre-corneal
surface decreases with time after topical application [16].
Thus,  the  traditional  LC50  determined  with  in  vitro
experiments cannot be used directly to determine drug toxicity
in the cornea. To solve this problem, the in vitro data have to
be converted to the tissue toxicity using cellular PK and PD
models. To illustrate how the new models could be used for
this purpose, we simulated the toxicity effect of ECA on
epithelial cells when the drug was applied topically on the
corneal surface for glaucoma treatment (see Figure 6). The
new  PK  and  PD  models  can  also  be  combined  with  the
mathematical model of ECA transport in the eye, developed
in our previous study [16], to improve the prediction on the
maximum ECA concentration that can be achieved in the TM
(CTM).  In  our  previous  study,  we  defined  a  threshold
concentration for toxicity, Ctox, which was the extracellular
concentration of ECA at which a certain percentage (e.g., 2%)
of cells would be killed after they were exposed continuously
to  the  drug  for  6  h.  The  value  of  Ctox  was  found  to  be
approximately 75 μM for corneal epithelial cells [43]. Based
on this information, we chose the initial drug concentration
(Ce0) in the pre-corneal surface to be 75 μM. This choice would
make sure that the majority of corneal epithelial cells were not
killed during the treatment since ECA concentration in the
interstitial fluid of cornea could not exceed 75 μM. Under this
condition, the ECA transport model would predict that the
peak  value  of  CTM  was  less  than  10  μM,  which  was  the
minimum effective concentration for improving the outflow
facility in human eyes ex vivo [44], no matter whether ECA
was released from a Pluronic® copolymer film or applied as
eye drops. Therefore, it seemed that ECA was not a good TM
drug candidate. However, the conclusion could be different if
the  new  PK  and  PD  models  were  used  to  calculate  the
maximum Ce0. For example, the new models predicted that the
maximum Ce0 could be increased to 312 μM if ECA was
released  from  the  Pluronic®  copolymer  film.  Under  this
condition, the predicted cell survival relative to control, S, was
98.1% in the cornea, which was the same as the value of S
when  the  cells  were  treated  continuously  with  an  ECA
solution at 75 μM for 6 h. Combining the new PK and PD
models with the model of ECA transport in the eye developed
Molecular Vision 2011; 17:2507-2515 <http://www.molvis.org/molvis/v17/a271> © 2011 Molecular Vision
2513in the previous study [16], we could predict that although
CTM varied with time, it would be higher than the minimum
effective concentration (i.e., 10 μM) for approximately 3 h.
This analysis demonstrated a unique application of the new
cellular PK and PD models for improving ECA delivery to the
TM.
Conclusions:  A  new  theoretical  framework  was
developed in this study that could be used to predict cellular
uptake and cell survival relative to control when treated with
ECA at different concentrations and for different periods.
More importantly, the prediction could be made even when
the extracellular concentration varied with time. The model
predictions were shown to be consistent with the data reported
in the literature. In future studies, the new model can be
combined with mathematical models of ECA transport in the
eye [16], to simultaneously simulate drug delivery to the TM
and  long-term  toxicity  of  ECA  in  corneal  tissues.  These
simulations  can  be  useful  for  optimizing  drug  dose  and
delivery schedule in glaucoma treatment.
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